- Home
- APVO vs CHEK Comparison
APVO vs CHEK Comparison
Compare APVO & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- CHEK
- Stock Information
- Founded
- APVO 2016
- CHEK 2004
- Country
- APVO United States
- CHEK Israel
- Employees
- APVO N/A
- CHEK N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- APVO Health Care
- CHEK Health Care
- Exchange
- APVO Nasdaq
- CHEK Nasdaq
- Market Cap
- APVO 4.1M
- CHEK 4.3M
- IPO Year
- APVO N/A
- CHEK 2015
- Fundamental
- Price
- APVO $3.23
- CHEK $0.77
- Analyst Decision
- APVO Strong Buy
- CHEK
- Analyst Count
- APVO 1
- CHEK 0
- Target Price
- APVO $5,920.00
- CHEK N/A
- AVG Volume (30 Days)
- APVO 6.6M
- CHEK 19.6K
- Earning Date
- APVO 08-07-2025
- CHEK 08-14-2025
- Dividend Yield
- APVO N/A
- CHEK N/A
- EPS Growth
- APVO N/A
- CHEK N/A
- EPS
- APVO N/A
- CHEK N/A
- Revenue
- APVO N/A
- CHEK N/A
- Revenue This Year
- APVO N/A
- CHEK N/A
- Revenue Next Year
- APVO N/A
- CHEK N/A
- P/E Ratio
- APVO N/A
- CHEK N/A
- Revenue Growth
- APVO N/A
- CHEK N/A
- 52 Week Low
- APVO $2.81
- CHEK $0.56
- 52 Week High
- APVO $485.37
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- APVO 34.28
- CHEK 45.27
- Support Level
- APVO $2.81
- CHEK $0.71
- Resistance Level
- APVO $13.11
- CHEK $0.77
- Average True Range (ATR)
- APVO 1.10
- CHEK 0.03
- MACD
- APVO 0.30
- CHEK -0.00
- Stochastic Oscillator
- APVO 4.08
- CHEK 46.23
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.